1. Introduction
===============

A number of cyclic *β*-amino acids exhibit biological activity (*e.g.* cispentacin \[[@B1-molecules-15-03998],[@B2-molecules-15-03998]\] and Icofungipen \[[@B3-molecules-15-03998],[@B4-molecules-15-03998]\]), and in addition they have also been used in peptide (modified activities and stabilities \[[@B5-molecules-15-03998]\] and well-defined three-dimensional structures \[[@B6-molecules-15-03998],[@B7-molecules-15-03998],[@B8-molecules-15-03998],[@B9-molecules-15-03998]\]), in heterocyclic \[[@B10-molecules-15-03998],[@B11-molecules-15-03998],[@B12-molecules-15-03998],[@B13-molecules-15-03998]\] and combinatorial \[[@B14-molecules-15-03998],[@B15-molecules-15-03998],[@B16-molecules-15-03998]\] chemistry, and in drug research \[[@B9-molecules-15-03998],[@B17-molecules-15-03998],[@B18-molecules-15-03998]\]. Hydroxylated *β*-amino acids represent a valuable class of amino acids, due to their importance from both biological and chemical aspects. In recent years, acyclic hydroxylated *β*-amino acids have attracted much attention especially following their recognition as an important class of compounds in the design and synthesis of potential pharmaceutical drugs \[e.g., Taxol® (paclitaxel) and its analogue Taxotère® (docetaxel)\] \[[@B17-molecules-15-03998],[@B19-molecules-15-03998],[@B20-molecules-15-03998],[@B21-molecules-15-03998]\]. Among the carbocyclic β-amino acids a number of hydroxylated β-amino acid derivatives present antibiotic (e.g., oryzoxymycin \[[@B22-molecules-15-03998]\]) or antifungal activity, and are building blocks for pharmaceutically important natural substances such as fortamine, chryscandin, pentopyranamine, gougerotin and blasticidin \[[@B20-molecules-15-03998],[@B23-molecules-15-03998]\].

Enzymatic methods for the preparation of several enantiomerically pure hydroxy-substituted carbocyclic *β*-amino acids or their derivatives have been published, but in those syntheses the enantioselective enzymatic step was performed for the preparation of starting *β*-amino acids \[[@B24-molecules-15-03998],[@B25-molecules-15-03998],[@B26-molecules-15-03998],[@B27-molecules-15-03998]\]. In contrast, in this work the aim was to introduce the chirality on the last step on the synthetic sequence leading to hydroxy-substituted *β*-amino esters. Our earlier extensive investigations on enzyme-catalyzed enantioselective hydrolysis of both carbocyclic \[[@B28-molecules-15-03998]\] and acyclic \[[@B29-molecules-15-03998],[@B30-molecules-15-03998],[@B31-molecules-15-03998]\] *β*-amino esters suggested the possibility of direct lipase-catalyzed resolution of hydroxy-substituted *β*-amino esters (1*R*\*,2*S*\*,5*S*\*)-(±)-**4**, (1*S*\*,2*S*\*,5*R*\*)-(±)-**5**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** and (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**, through enantioselective enzymatic hydrolysis.

2. Results and Discussion
=========================

2.1. Synthesis of hydroxy-substituted racemic β-amino esters (1*R*\*,2*S*\*,5*S*\*)-(±)-4, (1*S*\*,2*S*\*,5*S*\*)-(±)-5, (1*S*\*,2*S*\*,5*S*\*)-(±)-6 and (1*S*\*,2*S*\*,5*R*\*)-(±)-10
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The selective synthesis of the hydroxylated amino ester stereoisomers with a cyclohexene framework has been accomplished starting from *N*-Boc protected *cis*- or *trans*-2-aminocyclohex-3-enecarboxylic acid \[[@B32-molecules-15-03998]\] and was based on stereoselective iodolactonization followed by dehydroiodination and lactone opening. Thus, amino acid (1*R*,2*S*)-(±)-**1** on treatment with KI/I~2~ in the presence of NaHCO~3~ gave regioselectively iodolactone (1*R*\*,2*S\**,4*S*\*,5*S\**)-(±)-**2**, which was then subjected to dehydroiodination with DBU under basic conditions, affording unsaturated lactone (1*R*\*,2*S\**,5*S\**)-(±)-**3** ([Scheme 1](#molecules-15-03998-scheme1){ref-type="scheme"}). The hydroxyl function in the cyclohexene skeleton was introduced by lactone opening of (1*R*\*,2*S\**,5*S\**)-(±)-**3** with NaOEt. When the reaction was performed in EtOH at 0 °C for 1 h the *all-cis*-5-hydroxlated amino ester (1*R*\*,2*S*\*,5*S*\*)-(±)-**4** was formed in good yield. By contrast, upon reaction with NaOEt at 20 °C for 20 h lactone (1*R*\*,2*S\**,5*S\**)-(±)-**3** underwent epimerization at C-1 to give the hydroxylated amino ester stereoisomer (1*S*\*,2*S*\*,5*S*\*)-(±)-**5** ([Scheme 1](#molecules-15-03998-scheme1){ref-type="scheme"}). The desired saturated analog of (1*S*\*,2*S*\*,5*S*\*)-(±)-**6**was readily prepared in good yield by Pd catalyzed hydrogenation performed at room temperature and atmospheric pressure.

Other hydroxylated stereoiomers of (1*R*\*,2*S*\*,5*S*\*)-(±)-**4** and (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**could be prepared from *N*-Boc-protected amino acid (1*S\**,2*S\**)-(±)-**7** when submitted to iodolatonization, dehydroiodination, followed by lactone ring-opening with NaOEt to furnish selectively hydroxylated amino ester stereoisomer (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**([Scheme 2](#molecules-15-03998-scheme2){ref-type="scheme"}).

![Synthesis of (1*R*\*,2*S*\*,5*S*\*)-(±)-**4**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**5** and (1*S*\*,2*S*\*,5*S*\*)-(±)-**6**.](molecules-15-03998-g004){#molecules-15-03998-scheme1}

![Synthesis of (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**.](molecules-15-03998-g005){#molecules-15-03998-scheme2}

2.2. Enzymatic hydrolysis of hydroxy-substituted β-amino esters (1*S*\*,2*R*\*,5*R*\*)-(±)-4, (1*S*\*,2*S*\*,5*S*\*)-(±)-5, (1*S*\*,2*S*\*,5*S*\*)-(±)-6 and (1*S*\*,2*S*\*,5*R*\*)-(±)-10
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

On the basis of our earlier results on the enantioselective hydrolyses of *β-*amino esters using CAL-B and lipase PS in an organic solvent \[[@B28-molecules-15-03998],[@B29-molecules-15-03998],[@B30-molecules-15-03998],[@B31-molecules-15-03998]\] we carried out enzymatic screening experiments relating to the hydrolysis of (1*S*\*,2*S*\*,5*R*\*)-(±)-**10** ([Scheme 3](#molecules-15-03998-scheme3){ref-type="scheme"}) with 0.5 equiv. of H~2~O in *i-*Pr~2~O ([Table 1](#molecules-15-03998-t001){ref-type="table"}, entries 1 and 11-15). Excepting lipase AK (*Pseudomonas flurescens*), which practically did not show any selectivity, all the other lipases tested \[CAL-A (*Candida antarctica* lipase A), CAL-B (*Candida antarctica* lipase B), lipases PS (*Burkholderia cepacis*), AY (*Candida rugosa*) and PPL (porcine pancreatic lipase)\] all showed catalytic activity, but only CAL-B catalyzed the reaction at 60 ºC with moderate enantioselectivity (*ee~substrate~* 48% after 48 h). As it was later confirmed, the majority of the antipodes of unreacted *β*-amino acid ethyl ester enantiomers were consumed in side-reactions (polymerization).

In order to enhance the observed enantioselectivity, several solvents were tested in the CAL-B-catalyzed hydrolysis of (1*S*\*,2*S*\*,5*R*\*)-(±)-**10** at 60 ºC ([Table 1](#molecules-15-03998-t001){ref-type="table"}, entries 2-5). It could be appreciated that the reaction proceeded more slowly and less enantioselectively in *n*-hexane and 1,4-dioxane (entries 2 and 4), with better *E* and comparable reaction rate in toluene (entry 3) and with considerably higher *E* and higher reaction rate in *t-*BuOMe (entry 5) relative to *i*Pr~2~O (entry 1).

![Enzymatic hydrolysis of (1*S*\*,2*R*\*,5*R*\*)-(±)-**4**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** and (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**.](molecules-15-03998-g006){#molecules-15-03998-scheme3}

molecules-15-03998-t001_Table 1

###### 

Conversion and enantioselectivity of enzymatic hydrolysis of (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**^a^.

  Entry   Enzyme         Quantity of enzyme (mg mL^-1^)   Temperature (ºC.)   Solvent       Time (h)   *Conv*.^b^ (%)   *ee*~S~^c^(%)   *ee*~P~^d^(%)   *E* ^b^
  ------- -------------- -------------------------------- ------------------- ------------- ---------- ---------------- --------------- --------------- ---------
  1       CAL-B          30                               60                  *i*Pr~2~O     48         37               48              82              16
  2       CAL-B          30                               60                  *n*-hexane    48         24               18              58              4
  3       CAL-B          30                               60                  toluene       48         35               48              91              34
  4       CAL-B          30                               60                  1,4-dioxane   48         25               16              48              3
  5       CAL-B          30                               60                  *t-*BuOMe     48         45               75              91              48
  6       CAL-B          30                               50                  *t-*BuOMe     48         35               47              86              21
  7       CAL-B          30                               40                  *t-*BuOMe     48         36               46              81              15
  8       CAL-B          30                               70                  *t-*BuOMe     40         35               44              82              16
  9       CAL-B          50                               60                  *t-*BuOMe     40         40               53              81              16
  10      CAL-B          75                               60                  *t-*BuOMe     40         42               60              83              20
  11      Lipase PS^e^   30                               45                  *i*Pr~2~O     48         22               10              35              2
  12      CAL-A^e^       30                               45                  *i*Pr~2~O     48         44               7               9               1
  13      Lipase AY^e^   30                               45                  *i*Pr~2~O     48         11               2               16              1
  14      Lipase AK^e^   30                               45                  *i*Pr~2~O     48         25               1               3               1
  15      PPL            30                               45                  *i*Pr~2~O     48         20               5               20              2

^a^0.05 M substrate; ^b^Apparent values, calculated from *ee*for unreacted amino ester and *ee* for produced amino acid; ^c^According to GC or HPLC (Experimental Section); ^d^According to GC or HPLC after double derivatization (Experimental Section);^e^Contains 20% (w/w) of lipase adsorbed on Celite in the presence of sucrose.

On the basis of these preliminary results, preparative-scale resolutions of (1*S*\*,2*R*\*,5*R*\*)-(±)-**4**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** and (1*S*\*,2*S*\*,5*R*\*)-(±)-**10** were performed in *t*-BuOMe at 60 ºC in the presence of CAL-B (30 mg mL^-1^) with 0.5 equiv. of H~2~O. The results are summarized in [Table 2](#molecules-15-03998-t002){ref-type="table"} and the Experimental Section. It can be noted, that the hydroxy-substituted *β*-amino acid enantiomers (**11**−**14**) are missing from the Table, as above observed, the *β*-amino acid ethyl esters (1*S*,2*S*,5*R*)-**4**, (1*R*,2*R*,5*R*)-**5**, (1*R*,2*R*,5*R*)-**6** and (1*R*,2*R*,5*S*)-**10** underwent polymerization (the side-product(s) were not characterized). As it was confirmed for the product obtained from (1*S*,2*S*,5*R*)-**4**, the mass spectrum shows two major peaks. The mass difference between these two peaks is 259.4 m/z. This corresponds to the mass of one Boc-protected saturated amino acid. Furthermore the MS/MS spectra of these two peaks show losses of Boc groups and Boc-protected saturated amino acid residues. These results suggest the polymerization of the amino acid derivative. A possible pathway is the enzyme catalyzed Michael addition. The NMR results support this view, because the signals of the protons of the double bonds and the OH groups are missing. Since CAL-B showed *S*-selectivity towards the earlier performed hydrolyses of *cis* and *R*-selectivity of *trans* carbocyclic *β*-amino esters \[[@B28-molecules-15-03998]\], *S-*selectivity for hydrolysis of (1*S*\*,2*R*\*,5*R*\*)-(±)-**4**and *R*-selectivity for hydrolysis of (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** and (1*S*\*,2*S*\*,5*R*\*)-(±)-**10** has been assumed. These lipase-catalysed reactions of hydroxy-substituted *β*-amino esters presumably proceeds in two stages: first, the Ser OH attacks the carbonyl group of ester function and forms the acyl-enzyme intermediate and second, deacylation of the enzyme in combination with side reactions (polymerization) results the products (*β*-amino acid being one of them). Even though modelling has not been used, knowledge of the active site structure of CAL-B, together with the stereostructures of hydroxy-substituted *β*-amino esters (CS Chem 3D 6.0) and a consideration of the results obtained for the CAL-B-catalysed hydrolysis of ethyl *cis*-(2-aminocyclohex-3-ene)-1-carboxylate ([Figure 1](#molecules-15-03998-f001){ref-type="fig"}), can be utilized to predict the interaction between the substrate and the acyl binding site. [Figure 2](#molecules-15-03998-f002){ref-type="fig"} and [Figure 3](#molecules-15-03998-f003){ref-type="fig"} illustrate the possible accommodations for the enantiomers in the apparent active site of CAL-B (only the Ser residue is indicated), which suggest the proposed selectivities, since the orientations (1*R*,2*S*,5*S*)-**4**, (1*S*,2*S*,5*S*)-**5**, (1*S*,2*S*,5*S*)-**6** and (1*S*,2*S*,5*R*)-**10** do not appear to be appropriate to ensure Ser OH attack.

![*S*-selective hydrolysis of ethyl *cis*-(2-aminocyclohex-3-ene)-1-carboxylate \[[@B28-molecules-15-03998]\].](molecules-15-03998-g001){#molecules-15-03998-f001}

![*S*-selective hydrolysis of (1*S*\*,2*R*\*,5*R*\*)-(±)-**4**.](molecules-15-03998-g002){#molecules-15-03998-f002}

![*R*-selective hydrolysis of (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** and (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**.](molecules-15-03998-g003){#molecules-15-03998-f003}

molecules-15-03998-t002_Table 2

###### 

Lipase-catalyzed preparative-scale hydrolyses of (1*S*\*,2*R*\*,5*R*\*)-(±)-**4**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**, (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** and (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**^a^.

  Racemate                             Time (days)   *Conv*.^b^ (%)   Unreacted enantiomer                                  
  ------------------------------------ ------------- ---------------- ---------------------- ------------------------- ---- ------------------
  (1 *S*\*,2*R*\*,5*R*\*)-(±)-**4**    10            43               32                     (1*R*,2*S*,5*S*)-**4**    68   +34 (*c* 0.19)
  (1 *S*\*,2*S*\*,5*S*\*)-(±)-**5**    10            41               34                     (1*S*,2*S*,5*S*)-**5**    78   +16 (*c* 0.165)
  (1 *S*\*,2*S*\*,5*S*\*)-(±)-**6**    10            36               29                     (1*S*,2*S*,5*S*)-**6**    54   -4 (*c* 0.24)
  (1 *S*\*,2*S*\*,5*R*\*)-(±)-**10**   7             43               41                     (1*S*,2*S*,5*R*)-**10**   90   +100 (*c* 0.155)

^a^ 0.5 equiv. of H~2~O; CAL-B (30 mg mL^-1^) in *t-*BuOMe at 60 ºC; ^b^Calculated using an internal standard (*n*-heptadecane, GC); ^c^According to GC or HPLC (Experimental Section).

3. Experimental
===============

3.1. Materials and methods
--------------------------

CAL-B (lipase B from *Candida antarctica*, produced by the submerged fermentation of a genetically modified *Aspergillus oryzae* microorganism and adsorbed on a macroporous resin) and porcine pancreatic lipase (PPL) were from Sigma-Aldrich. CAL-A (lipase A from *Candida antarctica*) was purchased from Roche Diagnostics Corporation. Lipase PS-IM (immobilized on diatomaceous earth) and PS--SD (*Burkholderia cepacia*) were kind gifts from Amano Enzyme Europe Ltd. Lipase AK (*Pseudomonas fluorescens*) was from Amano Pharmaceuticals, and lipase AY (*Candida rugosa*) was from Fluka. All the chemicals were purchased from Aldrich or Fluka. The solvents were of the highest analytical grade. Melting points were determined with a Kofler apparatus. NMR spectra were recorded on a Bruker DRX 400 spectrometer. Chemical shifts are given in ppm relative to TMS as internal standard, with CDCl~3~ or DMSO as solvent. Optical rotations were measured with a Perkin-Elmer 341 polarimeter. The mass spectra were recorded on a Finnigan MAT 95S spectrometer. Elemental analyses were performed with a Perkin-Elmer CHNS-2400 Ser II Elemental Analyzer. Compounds (1*R*\*,2*S\**)-(±)-**1** and (1*S*\*,2*S\**)-(±)-**7** were prepared according to our earlier method \[[@B32-molecules-15-03998]\].

3.2. Typical small-scale enzymatic experiment
---------------------------------------------

Racemic substrate (0.05 M solution) in an organic solvent (1 mL) was added to the lipase tested (30, 50 or 75 mg mL^-1^). Water (0.5 equiv.) was next added. The mixture was shaken at 40, 50, 60 or 70 °C. The progress of the reaction was followed by taking samples from the reaction mixture at intervals and analysing them by GC or HPLC. The *ee* values for the unreacted β-amino ester (1*S*,2*S*,5*R*)-**10**and produced β-amino acid (1*R*,2*R*,5*S*)-**14**enantiomers were determined by using HPLC equipped with Chiralpak IA 5 µ column (0.4 cm × 1 cm), after derivatization (Ac~2~O in the presence of 4-dimethyl-aminopyridine and pyridine) for (1*S*,2*S*,5*R*)-**10**and double derivatization (CH~2~N~2~, Ac~2~O in the presence of 4-dimethylaminopyridine and pyridine) \[[@B33-molecules-15-03998]\] for (1*R*,2*R*,5*S*)-**14**\[the mobile phase: *n*-hexane/2-propanol (90/10); flow rate 0.5 mL min^-1^; detection at 205 nm; retention times (min); (1*S*,2*S*,5*R*)-**10**: 28.96 (antipode: 24.96); (1*R*,2*R*,5*S*)-**14**: 28,06 (antipode: 36.05)\]. The *ee* values for (1*R*,2*S*,5*S*)-**4**, (1*S*,2*S*,5*S*)-**5,**(1*S*,2*S*,5*S*)-**6,**(1*S*,2*R*,5*R*)-**11**, (1*R*,2*R*,5*R*)-**12**and (1*R*,2*R*,5*R*)-**13,**were determined by using GC equipped with Chromopack Chiralsil-Dex CB column (25 m) after derivatization with CH~2~N~2~ \[[@B33-molecules-15-03998]\] \[190 °C; 140 kPa; retention times (min): (1*S*,2*S*,5*S*)-**5**: 12.67 (antipode: 13.28); (1*R*,2*R*,5*R*)-**12**: 11.80 (antipode: 11.30); (1*S*,2*S*,5*S*)-**6**: 13,29 (antipode: 14.51); (1*R*,2*R*,5*R*)-**13**: 12.87 (antipode: 12.38)\], \[170 °C; 140 kPa; retention times (min): (1*R*,2*S*,5*S*)-**4**: 27.06 (antipode: 28.12); (1*S*,2*R*,5*R*)-**11**: 14.47 (antipode: 13.76)\].

3.3. Synthesis of iodolactones tert-butyl (1R\*,2S\*,4S\*,5S\*)-4-iodo-7-oxo-6-oxabicyclo\[3.2.1\]octan-2-ylcarbamate \[(1R\*,2S\*,4S\*,5S\*)-(±)-2\] and tert-butyl (1S\*,2S\*,4R\*,5R\*)-4-iodo-7-oxo-6-oxabicyclo-\[3.2.1\]octan-2-ylcarbamate \[(1S\*,2S\*,4R\*,5R\*)-(±)-8\] \[[@B32-molecules-15-03998]\]
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a solution of *N*-Boc-protected amino acid \[36 mmol (1*R*\*,2*S\**)-(±)-**1** or (1*S*\*,2*S\**)-(±)-**7**\] in CH~2~Cl~2~ (200 mL), KI (5 equiv, 180 mmol), NaHCO~3~ (4 equiv, 144 mmol), H~2~O (200 mL) and I~2~ (2.1 equiv, 75 mmol) were added. After stirring for 12 h at room temperature, the mixture was taken up in CH~2~Cl~2~ (300 mL), and washed with saturated aqueous Na~2~SO~3~ solution. The organic layer was then dried (Na~2~SO~4~) and concentrated under reduced pressure and resulted (1*R*\*,2*S\**,4*S*\*,5*S\**)-(±)-**2** \[white solid; yield: 75%; mp 180--183 °C (*n*-hexane); (R~f~ = 0.7, *n*-hexane-EtOAc 2:1)\] or (1*S*\*,2*S\**,4*R*\*,5*R\**)-(±)-**8** \[white solid; yield: 83%; mp 128--130 °C (*n*-hexane); (R~f~ = 0.65, *n*-hexane-EtOAc 2:1)\].

^1^H-NMR (400 MHz, CDCl~3~) for (1*R*\*,2*S\**,4*S*\*,5*S\**)-(±)-**2**: δ = 1.48 (s, 9H, *t*Bu), 2.13--2.23 (m, 1H, CH~2~), 2.45--2.53 (m, 2H, CH~2~), 2.79--2.90 (m, 2H, H-1 and CH~2~), 4.16--4.22 (m, 1H, H-4), 4.48--4.53 (m, 1H, H-2), 4.78 (brs, 1H, N-H), 4.80--4.85 (m, 1H, H-5); ^13^C-NMR (100 MHz, CDCl~3~): δ = 20.8, 28.7, 33.9, 36.9, 44.9, 46.1, 80.1, 82.0, 156.8, 172.0.

^1^H-NMR (400 MHz, CDCl~3~) for (1*S*\*,2*S\**,4*R*\*,5*R\**)-(±)-**8**: δ = 1.50 (s, 9H, *t*Bu), 2.23--2.30 (m, 1H, CH~2~), 2.33--2.43 (m, 1H, CH~2~), 2.87--3.07 (m, 3H, H-1 and CH~2~), 4.22--4.25 (m, 1H, H-4), 4.38--4.43 (m, 1H, H-2), 4.88--4.93 (m, 1H, H-5), 5.38 (brs, 1H, N-H); ^13^C-NMR (100 MHz, CDCl~3~): δ = 20.1, 28.5, 29.1, 33.9, 43.0, 46.6, 79.4, 81.7, 177.0, 179.0.

3.4. Dehydroiodination reactions to obtain tert-butyl (1R\*,2S\*,5S\*)-7-oxo-6-oxabicyclo\[3.2.1\]oct-3-en-2-ylcarbamate \[(1R\*,2S\*,5S\*)-(±)-3\] and tert-butyl (1S\*,2S\*,5R\*)-7-oxo-6-oxabicyclo\[3.2.1\]oct-3-en-2-ylcarbamate \[(1S\*,2S\*,5R\*)-(±)-9\]
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a solution of iodolactone \[12 mmol (1*R*\*,2*S\**,4*S*\*,5*S\**)-(±)-**2**or (1*S*\*,2*S\**,4*R*\*,5*R\**)-(±)-**8**\] in THF (60 mL) DBU (2.1 equiv, 25.2 mmol) was added and the mixture was stirred at 65 °C for 4 h. Then the solution was concentrated under reduced pressure and the residue was taken up in EtOAc (140 mL). The organic layer was washed with H~2~O (3 x 70 mL), dried (Na~2~SO~4~) and concentrated under vacuum. The residue was crystallized from *n*-hexane-EtOAc and resulted (1*R*\*,2*S\**,5*S\**)-(±)-**3**\[white solid; yield: 72%; mp 148--149 °C (*n*-hexane-EtOAc); (R~f~ = 0.6, *n*-hexane-EtOAc 2:1)\] or (1*S*\*,2*S\**,5*R\**)-(±)-**9** \[white solid; yield: 71%; mp 149--151 °C (*n*-hexane); (R~f~ = 0.6, *n*-hexane-EtOAc 2:1)\].

^1^H-NMR (400 MHz, CDCl~3~) for (1*R*\*,2*S\**,5*S\**)-(±)-**3**: δ = 1.48 (s, 9H, *t*Bu), 2.16--2.22 (m, 1H, CH~2~), 2.54--2.63 (m, 1H, CH~2~), 3.01--3.06 (m, 1H, H-1), 4.66--4.72 (m, 1H, H-2), 4.48--4.53 (m, 1H, H-2), 4.81--4.85 (m, 1H-5), 4.90 (brs, 1H, N-H), 5.78--5.82 (m, 1H, H-3), 6.30--6.37 (m, 1H, H-4); ^13^C-NMR (100 MHz, CDCl~3~): δ = 28.7, 37.1, 44.1, 48.9, 73.5, 80.6, 131.1, 132.1, 158.8, 172.4.

^1^H-NMR (400 MHz, DMSO) for (1*S*\*,2*S\**,5*R\**)-(±)-**9**: δ = 1.42 (s, 9H, *t*Bu), 2.28--2.36 (m, 2H, CH~2~), 2.69--2.75 (m, 1H, H-1), 4.20--4.28 (m, 1H, H-2), 4.71--4.76 (m, 1H, H-5), 5.59--5.65 (m, 1H, H-3), 6.40--6.46 (m, 1H, H-4), 7.48 (brs, 1H, N-H).^13^C-NMR (100 MHz, DMSO): 29.1, 31.5, 44.4, 47.6, 73.9, 79.4, 131.1, 132.9, 155.7, 178.2.

3.5. Lactone ring opening reaction to obtain ethyl (1R\*,2S\*,5S\*)-2-(tert-butoxycarbonylamino)-5-hydroxycyclohex-3-enecarboxylate \[(1R\*,2S\*,5S\*)-(±)-4\], ethyl (1S\*,2S\*,5S\*)-2-(tert-butoxycarbonyl-amino)-5-hydroxycyclohex-3-enecarboxylate \[(1S\*,2S\*,5S\*)-(±)-5\] and ethyl (1S\*,2S\*,5R\*)-2-(tert-butoxycarbonylamino)-5-hydroxycyclohex-3-enecarboxylate \[(1S\*,2S\*,5R\*)-(±)-10\]
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a solution of unsaturated lactone \[4 mmol of (1*R*\*,2*S\**,5*S\**)-(±)-**3**or (1*S*\*,2*S\**,5*R\**)-(±)-**9**)\] in anhydrous EtOH (20 mL) NaOEt (1.2 equiv, 4.8 mmol) was added at 0 °C and the reaction mixture was further stirred at the temperature and time indicated. Then the EtOH was removed under reduced pressure at 40 °C and the residue was taken up in EtOAc (50 mL). The organic layer was washed with H~2~O (3 × 25 mL), dried (Na~2~SO~4~) and concentrated under reduced pressure. The crude residue was crystallized from *n*-hexane-EtOAc to give the desired product:

(1*R*\*,2*S*\*,5*S*\*)-(±)-**4**: white solid; yield: 67%; mp 88--90 °C (*n*-hexane-EtOAc); (R~f~ = 0.4, *n*-hexane-EtOAc 1:1). ^1^H-NMR (400 MHz, CDCl~3~): δ = 1.26 (t, 3H, CH~3~), 1.42 (s, 9H, *t*Bu), 1.88--1.65 (m, 1H, CH~2~), 2.09--2.17 (m, 1H, CH~2~), 2.84--2.91 (m, 1H, H-1), 4.08--4.18 (m, 3H, OCH~2~ and H-2), 4.46--4.50 (m, 1H, H-5), 4.90 (brs, 1H, N-H), 5.67--5.71 (m, 1H, H-3), 5.82--5.88 (m, 1H, H-4); ^13^C-NMR (100 MHz, CDCl~3~): δ = 14.8, 29.0, 29.7, 42.9, 45.8, 61.6, 66.2, 78.6, 126.9, 125.9, 155.6, 172.8.

(1*S*\*,2*S*\*,5*S*\*)-(±)-**5**: white solid; yield: 78%; mp 107--108 °C (*n*-hexane-EtOAc); (R~f~ = 0.35, *n*-hexane-EtOAc 1:1). ^1^H-NMR (400 MHz, DMSO): δ = 1.18 (t, 3H, CH~3~), 1.37 (s, 9H, *t*Bu), 1.72--1.80 (m, 2H, CH~2~), 2.67--2.70 (m, 1H, H-1), 4.00--4.15 (m, 4H, OCH~2~, H-2 and H-5), 4.86 (brs, 1H, O-H), 5.46--5.52 (m, 1H, H-3), 5.68--5.73 (m, 1H, H-4), 6.68 (brs, 1H, N-H); ^13^C-NMR (100 MHz, DMSO): δ = 14.8, 29.1, 34.3, 41.8, 49.3, 60.8, 61.6, 78.6, 131.0, 131.4, 156.0, 174.6.

(1*S*\*,2*S*\*,5*R*\*)-(±)-**10**: white solid; yield: 64%; mp 130--133 °C (*n*-hexane-EtOAc); (R~f~ = 0.4, *n*-hexane-EtOAc 1:1). ^1^H-NMR (400 MHz, DMSO): δ = 1.17 (t, 3H, CH~3~, *J* = 7.15 Hz), 1.36 (s, 9H, *t*Bu), 1.46--1.53 (m, 1H, CH~2~), 1.97--2.07 (m, 1H, CH~2~), 3.96--4.11 (m, 3H, OCH~2~ and H-2), 4.18--4.25 (m, 1H, H-5), 4.90 (brs, 1H, O-H), 5.35--5.40 (m, 1H, H-3), 5.59--5.63 (m, 1H, H-4), 6.93 (brs, 1H, N-H); ^13^C-NMR (100 MHz, DMSO): δ = 14.9, 29.1, 36.1, 45.9, 49.6, 60.9, 65.6, 78.6, 129.9, 134.3, 155.9, 173.8.

3.6. Preparation of ethyl (1S\*,2S\*,5S\*)-2-(tert-butoxycarbonylamino)-5-hydroxycyclohexane­carboxylate \[(1S\*,2S\*,5S\*)-(±)-6\]
-----------------------------------------------------------------------------------------------------------------------------------

A solution of (1*S*\*,2*S*\*,5*S*\*)-(±)-**5** (200 mg), 10% Pd/C (40 mg) in EtOAc (15 mL) was stirred under H~2~ atmosphere at room temperature for 2 h. Then the Pd was filtered off through Celite and the filtrate was concentrated under reduced pressure. The crude product was purified on column chromatography on silica gel (*n*-hexane-EtOAc 1:1) and resulted (1*S*\*,2*S*\*,5*S*\*)-(±)-**6** as a colourless oil; yield: 89%; (R~f~ = 0.4, *n*-hexane-EtOAc 1:1). ^1^H-NMR (400 MHz, CDCl~3~): δ = 1.24 (t, 3H, CH~3~, *J*= 7.10 Hz), 1.42 (s, 9H, *t*Bu), 1.57--2.00 (m, 6 H, CH~2~, 2.68--2.79 (m, 1H, H-1), 3.68--3.80 (m, 1H, H-2), 4.07--4.20 (m, 3H, OCH~2~ and H-5), 4.61 (brs, 1H, N-H). ^13^C-NMR (100 MHz, CDCl~3~): δ = 14.6, 27.2, 28.7, 31.6, 35.1, 44.6, 50.9, 61.0, 65.0, 79.7, 155.4, 174.3.

3.7. Preparative-scale resolution of (1R\*,2S\*,5S\*)-(±)-4
-----------------------------------------------------------

Compound (1*R*\*,2*S*\*,5*S*\*)-(±)-**4**(200 mg, 0.70 mmol) was dissolved in *t*-BuOMe (40 mL). CAL-B (1 g, 25 mg mL^-1^) and H~2~O (6.3 μL, 0.35 mmol) were added and the mixture was shaken in an incubator shaker at 60 °C for 10 days. The reaction was stopped by filtering off the enzyme at 43% conversion. The solvent was evaporated off, and the residue purified by column chromatography (*n*-hexane:EtOAc 1:3); (R~f~ = 0.6, *n*-hexane-EtOAc 1:3) to give (1*R*,2*S*,5*S*)-**4** \[68 mg, 32%; \[α\]~D~^25^ = +34 (*c* 0.19 EtOH); m.p. 69--71 °C;*ee* = 74%\]. The filtered-off enzyme was washed with distilled H~2~O (3 x 15 mL), than with MeOH (3 x 15 mL) and the combined solvents was evaporated off, yielding the mixture of mainly polymeric products and amino acid. ^1^H-NMR (400 MHz, CDCl~3~, 25 °C, TMS) data for (1*R*,2*S*,5*S*)-**4** were similar to those for (1*R*\*,2*S*\*,5*S*\*)-(±)-**4**. Analysis: calculated for C~14~H~23~NO~5~ (285.34): C, 58.93; H, 8.12; N, 4.91; found: C, 58.80; H, 8.08; N, 4.92.

3.8. Preparative-scale resolution of (1S\*,2S\*,5S\*)-(±)-**5**
---------------------------------------------------------------

Following the procedure described above, the reaction of racemic (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**(200 mg, 0.70 mmol) and H~2~O (6.3 μL, 0.35 mmol) in *t*-BuOMe (40 mL) on the presence of CAL-B (1 g, 25 mg mL^-1^) at 60 °C afforded after 10 days (1*S*,2*S*,5*S*)-**5** \[64 mg, 32%; \[α\]~D~^25^ = +16 (*c* 0.165 EtOH); m.p. 100--102 °C;*ee* = 78%\]. ^1^H-NMR (400 MHz, CDCl~3~, 25 °C, TMS) data for (1*S*,2*S*,5*S*)-**5** were similar to those for (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**. Analysis: calculated for C~14~H~23~NO~5~ (285.34): C, 58.93; H, 8.12; N, 4.91; found: C, 58.80; H, 8.08; N, 4.92.

3.9. Preparative-scale resolution of (1S\*,2S\*,5S\*)-(±)-**6**
---------------------------------------------------------------

Following the procedure described above, the reaction of racemic (1*S*\*,2*S*\*,5*S*\*)-(±)-**6**(200 mg, 0.69 mmol) and H~2~O (6.3 μL, 0.35 mmol) in *t*-BuOMe (40 mL) on the presence of CAL-B (1 g, 25 mg mL^-1^) at 60 °C afforded after 10 days (1*S*,2*S*,5*S*)-**6** \[58 mg, 29%; \[α\]~D~^25^ = -4 (*c* 0.24 EtOH); yellowish oil;*ee* = 54%\]. ^1^H-NMR (400 MHz, CDCl~3~, 25 °C, TMS) data for (1*S*,2*S*,5*S*)-**6** were similar to those for (1*S*\*,2*S*\*,5*S*\*)-(±)-**6**. Analysis: calculated for C~14~H~25~NO~5~ (287.35): C, 58.52; H, 8.77; N, 4.87; found: C, 58.66; H, 8.62; N, 4.85.

3.10. Preparative-scale resolution of (1S\*,2S\*,5R\*)-(±)-**10**
-----------------------------------------------------------------

Following the procedure described above, the reaction of racemic (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**(200 mg, 0.70 mmol) and H~2~O (6.3 μL, 0.35 mmol) in *t*-BuOMe (40 mL) on the presence of CAL-B (1 g, 25 mg mL^-1^) at 60 °C afforded after 7 days (1*S*,2*S*,5*R*)-**10** \[97 mg, 0.48%; \[α\]~D~^25^ = +100 (*c* 0.18 EtOH); m.p. 142--144 °C;*ee* = 90%\]. ^1^H-NMR (400 MHz, CDCl~3~, 25 °C, TMS) data for (1*R*,2*R*,5*R*)-**5** were similar to those for (1*S*\*,2*S*\*,5*S*\*)-(±)-**5**. ^1^H-NMR (400 MHz, CDCl~3~, 25 °C, TMS) data for (1*S*,2*S*,5*R*)-**10** were similar to those for (1*S*\*,2*S*\*,5*R*\*)-(±)-**10**. Analysis: calculated for C~14~H~23~NO~5~ (285.34): C, 58.93; H, 8.12; N, 4.91; found: C, 58.91; H, 8.00; N, 4.97.

4. Conclusions
==============

Four hydroxy-substituted *β*-amino ester stereoisomers were resolved through a simple direct enzymatic method, involving CAL-B-catalyzed enantioselective hydrolysis in organic media. Moderate to good enantiomeric excess values (*ee* ≥ 52%) were obtained for the unreacted amino esters when the reactions were performed with 0.5 equiv. of added H~2~O, in *t-*BuOMe, at 60 ºC. Due to polymerization, the supposed *β*-amino acid enantiomers practically could not be isolated.
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